WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Read the full story below: CAPA examined how the IPR process struck down a patent relating to the […]

Continue Reading

WHAT YOU NEED TO KNOW What The Next U.S. Patent and Trademark Office (USPTO) Director Could Mean For Drug Prices: As anticipation builds around who the next USPTO director will be, the Coalition Against Patent Abuse (CAPA) is highlighting the importance of making the right choice to tackle anti-competitive behavior that will help lower drug prices.  […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System.  Part IV: IPR & Heart Disease – Knocking Down Erroneously Extended Patents. Read the full story below: In 2017, the patent for an anti-clotting drug prasugrel, under […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Stresses Importance Of Next USPTO Director – This week, CAPA Executive Director Matthew Lane penned an op-ed in STAT News highlighting the crucial role that the next U.S. Patent and Trademark Office Director will have on reducing drug costs for millions of American patients, many of which are already struggling financially […]

Continue Reading

WHAT YOU NEED TO KNOW We’re two months into the new year and the Coalition Against Patent Abuse (CAPA) is continuing to highlight why Congress should act to address abuses of the U.S. patent system. Many Big Pharma companies regular engage in tactics that can extend government-granted monopolies and illegitimately keep drug prices high for […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part II: IPR & Zytiga – Competition Matters – Here, CAPA looks at how the IPR proceeding for the prostate cancer medicine Zytiga accelerated patient access to generic […]

Continue Reading

WHAT YOU NEED TO KNOW BY THE NUMBERS – A new Morning Consult poll conducted for the Campaign for Sustainable Rx Pricing (CSRxP) – a member of CAPA – found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform the U.S. healthcare system to lower costs and put […]

Continue Reading

WHAT YOU NEED TO KNOW MUST READ: CAPA Warns Recent Federal Circuit Court Decision Could Erode Hatch-Waxman, Lead to Even Higher Drug Prices Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), recently authored an op-ed in Bloomberg Law around the Federal Circuit’s recent decision in GlaxoSmithKline LLCTeva Pharmaceuticals USA, Inc.: “The Federal Circuit’s decision in GlaxoSmithKline […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Files Amicus Brief Urging the Supreme Court to Preserve IPR to Lower Drug Prices. DID YOU KNOW – The U.S. Supreme Court is reviewing Arthrex Inc. v. Smith & Nephew Inc. to determine the constitutionality of the Patent Trial and Appeal Board (PTAB). In an amicus brief filed recently, CAPA outlined […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA: The USPTO must prioritize patent quality and restore the IPR system to its proper focus. UPDATE – As part of its ongoing campaign to safeguard the U.S. patent system and stop Big Pharma from gaming the system, CAPA filed comments this week with the United States Patent and Trademark Office (USPTO).  The […]

Continue Reading